Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sea cucumber extract is a marine-derived natural product being investigated for the treatment of osteoarthritis. Derived from holothurians (sea cucumbers), it is rich in bioactive compounds such as chondroitin sulfate, mucopolysaccharides, and other glycosaminoglycans. These components are reported to possess anti-inflammatory and antinociceptive properties, which may help alleviate joint pain and improve physical function in patients with degenerative joint disease. Faulding Healthcare Pty Ltd has evaluated the extract in a randomised, double-blind, placebo-controlled clinical trial, both as a monotherapy and in combination with Boswellia serrata extract. As a nutraceutical or natural health product, it aims to provide structural support to cartilage and modulate inflammatory pathways associated with joint degradation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sea cucumber extract.